AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36528677 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) viral load testing
Number of subjects: 68
Study 36528677 — intervention group
Group type: COMPARATOR
Intervention: Centralized viral load testing
Number of subjects: 68
Study 36528682 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident hypertension
Number of subjects: 152
Study 36528682 — intervention group
Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 152
Study 36528682 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning clustering
Number of subjects: 152
Study 36528761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral anterior 1-s RMS on the neck
Number of subjects: 0
Study 36528761 — intervention group
Group type: EXPERIMENTAL
Intervention: Different coil shapes and stimulation locations
Number of subjects: 0
Study 36528761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation over 10 min
Number of subjects: 0
Study 36528793 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8601 (3 mg total, 30 epicardial injections)
Number of subjects: 30
Study 36528793 — intervention group
Group type: COMPARATOR
Intervention: Placebo in citrate-buffered saline
Number of subjects: 30
Study 36528982 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic Training (AT)
Number of subjects: 63
Study 36528982 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 63
Study 36528984 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF)
Number of subjects: 66
Study 36528984 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 66
Study 36528984 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 36528997 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise training program (one 60 min group exercise session per week for 8 weeks + online home exercise program for 8 weeks)
Number of subjects: 167
Study 36528997 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise training program
Number of subjects: 167
Study 36529030 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma-induced protein-10 (IP-10) concentrations of 2000 pg/ml or higher
Number of subjects: 534
Study 36529030 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra treatment
Number of subjects: 534
Study 36529030 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein (CRP) and TNF-related apoptosis-inducing ligand (TRAIL)
Number of subjects: 534
Study 36529052 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac (first dose on D0, second dose on D28, booster dose on D210)
Number of subjects: 53
Study 36529052 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac
Number of subjects: 53
Study 36529052 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of CoronaVac (D240)
Number of subjects: 53
Study 36529052 — intervention group
Group type: COMPARATOR
Intervention: Prednisone treatment
Number of subjects: 53
Study 36529089 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release calcifediol (ERC) 300 mcg on days 1-3 and 60 mcg on days 4-27
Number of subjects: 171
Study 36529089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 36529089 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release calcifediol (ERC)
Number of subjects: 171
Study 36529106 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease and insomnia (ADI)
Number of subjects: 1076
Study 36529106 — intervention group
Group type: COMPARATOR
Intervention: Elderly individuals with insomnia (EI)
Number of subjects: 1076
Study 36529145 — intervention group
Group type: EXPERIMENTAL
Intervention: KCd consolidation group (carfilzomib-cyclophosphamide-dexamethasone)
Number of subjects: 281
Study 36529145 — intervention group
Group type: COMPARATOR
Intervention: HSCT group (autologous haematopoietic stem-cell transplantation)
Number of subjects: 281
Study 36529145 — intervention group
Group type: EXPERIMENTAL
Intervention: KCd induction and consolidation
Number of subjects: 281
Study 36529145 — intervention group
Group type: EXPERIMENTAL
Intervention: KCd maintenance
Number of subjects: 281
Study 36529145 — intervention group
Group type: COMPARATOR
Intervention: HSCT maintenance
Number of subjects: 281
Study 36529145 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment-related serious adverse events
Number of subjects: 281
Study 36529145 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent deaths during induction
Number of subjects: 281
Study 36529145 — intervention group
Group type: COMPARATOR
Intervention: Treatment-emergent deaths during maintenance after HSCT
Number of subjects: 281
Study 36529152 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential transarterial chemoembolisation (TACE) followed by stereotactic body radiotherapy (27·5-40·0 Gy in five fractions) and avelumab (10 mg/kg) administered 14 days after radiotherapy and every 2 weeks thereafter.
Number of subjects: 33
Study 36529152 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE followed by stereotactic body radiotherapy and avelumab.
Number of subjects: 33
Study 36529417 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported flares
Number of subjects: 222
Study 36529417 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-reported flares
Number of subjects: 222
Study 36529417 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening in DAPSA
Number of subjects: 222
Study 36529417 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition to flare state
Number of subjects: 222
Study 36529417 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between definitions of worsening
Number of subjects: 222
Study 36529613 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001 + irinotecan (RxI)
Number of subjects: 34
Study 36529613 — intervention group
Group type: COMPARATOR
Intervention: Single-agent regorafenib (RegI)
Number of subjects: 34
Study 36529709 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lacosamide infusion (2-12 mg/kg/day or 100-600 mg/day; 15-60 minutes infusion)
Number of subjects: 103
Study 36529709 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lacosamide infusion
Number of subjects: 103
Study 36529781 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Number of subjects: 6463
Study 36529781 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement
Number of subjects: 6463
Study 36529811 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab plus topical corticosteroids (200 mg for 5 kg to < 15 kg; 300 mg for 15 kg to < 30 kg) every 4 weeks for 16 weeks
Number of subjects: 161
Study 36529811 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus topical corticosteroids
Number of subjects: 161
Study 36529836 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizanlizumab (0.2-8 mg/kg body weight)
Number of subjects: 0
Study 36529836 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizanlizumab
Number of subjects: 0
Study 36529949 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin
Number of subjects: 0
Study 36529949 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 0
Study 36529989 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive genomic analysis
Number of subjects: 188
Study 36529993 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity statin with ezetimibe combination therapy
Number of subjects: 1398
Study 36529993 — intervention group
Group type: COMPARATOR
Intervention: High-intensity statin monotherapy
Number of subjects: 1398
Study 36530003 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of maternal and newborn care (QMNC) during the COVID-19 pandemic
Number of subjects: 4817
Study 36530003 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to routine antenatal care
Number of subjects: 4817
Study 36530003 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a companion during childbirth
Number of subjects: 4817
Study 36530003 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of personal protective equipment by health workers
Number of subjects: 4817
Study 36530003 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficiency of health workers
Number of subjects: 4817
Study 36530003 — intervention group
Group type: EXPERIMENTAL
Intervention: Episiotomy rates in spontaneous vaginal births
Number of subjects: 4817
Study 36530003 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding support
Number of subjects: 4817
Study 36530003 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with dignity
Number of subjects: 4817
Study 36530003 — intervention group
Group type: EXPERIMENTAL
Intervention: Suffering abuse during childbirth
Number of subjects: 4817
Study 36530003 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal payments made during childbirth
Number of subjects: 4817
Study 36530003 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of maternal and newborn care index by country
Number of subjects: 4817
Study 36530009 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective cesarean
Number of subjects: 620
Study 36530009 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency cesarean
Number of subjects: 620
Study 36530009 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous vaginal birth (SVB)
Number of subjects: 620
Study 36530007 — intervention group
Group type: EXPERIMENTAL
Intervention: Private facilities
Number of subjects: 25206
Study 36530007 — intervention group
Group type: COMPARATOR
Intervention: Public facilities
Number of subjects: 25206
Study 36530013 — intervention group
Group type: COMPARATOR
Intervention: 2020
Number of subjects: 2079
Study 36530013 — intervention group
Group type: COMPARATOR
Intervention: 2021
Number of subjects: 2079
Study 36530013 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (women who went into labor)
Number of subjects: 2079
Study 36530013 — intervention group
Group type: COMPARATOR
Intervention: QMNC index
Number of subjects: 2079
Study 36530383 — intervention group
Group type: EXPERIMENTAL
Intervention: WatchPAT sleep monitor for home-based sleep assessment, including detection of sleep apnea
Number of subjects: 37
Study 36530383 — intervention group
Group type: EXPERIMENTAL
Intervention: VA mobile app Cognitive Behavioral Therapy for Insomnia (CBT-i Coach)
Number of subjects: 37
Study 36530873 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone Position (PP)
Number of subjects: 40
Study 36531070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-Pulse Stimulation™ (NPS™) therapy
Number of subjects: 30
Study 36531168 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day fasting for 30 hours every other day for 6 weeks
Number of subjects: 23
Study 36531460 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacilli-loaded vaginal capsules (one capsule per day for 10 days)
Number of subjects: 74
Study 36531460 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one capsule per day for 10 days)
Number of subjects: 74
Study 36531700 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium scoring (CAC) on standard of care non-contrast chest CT (NCCT) imaging
Number of subjects: 193
Study 36531700 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium scoring (CAC)
Number of subjects: 193
Study 36531733 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel transthoracic echocardiographic (TTE) parameters including left ventricular ejection fraction (LVEF) ≤ 48% and ratios of LVEF and left atrial diameter (LAD) ≤ 1.1
Number of subjects: 3109
Study 36531733 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF) ≤ 48%
Number of subjects: 3109
Study 36531733 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratios of LVEF and left atrial diameter (LAD) ≤ 1.1
Number of subjects: 3109
Study 36531736 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct-related artery (IRA)-IMR assessment after successful primary percutaneous coronary angioplasty (PPCI)
Number of subjects: 242
Study 36531736 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher IMR values
Number of subjects: 242
Study 36531736 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite of cardiovascular death, re-infarction, re-hospitalization for heart failure, resuscitation or appropriate ICD shock at 1-year follow-up
Number of subjects: 242
Study 36531900 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance tobramycin inhalation solution (TIS) once daily
Number of subjects: 0
Study 36531900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36532014 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-directed Piggy Bac CAR T cell therapy (pbCAR-T)
Number of subjects: 1
Study 36532031 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63 MVA ME-TRAP vaccine
Number of subjects: 0
Study 36532058 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of subcutaneous atacicept
Number of subjects: 0
Study 36532058 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly administrations of atacicept for one year
Number of subjects: 0
Study 36532058 — intervention group
Group type: EXPERIMENTAL
Intervention: Single administration of atacicept
Number of subjects: 0
Study 36532191 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive screen time during COVID-19 lockdown
Number of subjects: 249
Study 36532191 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased screen time since COVID-19 pandemic
Number of subjects: 249
Study 36532191 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related screen time
Number of subjects: 249
Study 36532191 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for excessive screen time in children
Number of subjects: 249
Study 36532191 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for excessive screen time in adolescents
Number of subjects: 249
Study 36532545 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 g eicosapentaenoic acid (EPA) + 1.2 g docosahexaenoic acid (DHA)/day for 6 months
Number of subjects: 49
Study 36532545 — intervention group
Group type: COMPARATOR
Intervention: Observation for 6 months
Number of subjects: 49
Study 36532582 — intervention group
Group type: EXPERIMENTAL
Intervention: Photosynthetic scaffold for dermal regeneration, illuminated to promote local oxygen production, followed by autograft implantation.
Number of subjects: 1
Study 36532582 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermal vacuum massage therapy (as an adjunct to the main intervention).
Number of subjects: 1
Study 36532775 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine
Number of subjects: 0
Study 36532775 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine
Number of subjects: 0
Study 36533429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Number of subjects: 187
Study 36533429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (cisplatin + 5-fluorouracil or capecitabine)
Number of subjects: 187
Study 36533429 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (control)
Number of subjects: 187
Study 36533429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 187
Study 36533429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 187
Study 36533519 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasso+ centrifuged samples
Number of subjects: 36
Study 36533519 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasso+ whole blood samples
Number of subjects: 36
Study 36533519 — intervention group
Group type: COMPARATOR
Intervention: Standard venipuncture
Number of subjects: 36
Study 36533520 — intervention group
Group type: EXPERIMENTAL
Intervention: Posthospitalization behaviors
Number of subjects: 550
Study 36533622 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical treatment plus endovascular treatment (EVT)
Number of subjects: 572
Study 36533622 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment alone
Number of subjects: 572
Study 36533626 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Therapy (SET), 3 times weekly for 6 months (maximum 77 sessions)
Number of subjects: 272
Study 36533626 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 272
Study 36533748 — intervention group
Group type: EXPERIMENTAL
Intervention: AMD patients with various stages of AMD (stage 2 and stage 3)
Number of subjects: 458
Study 36533797 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-free bipolar radiofrequency device; 3 total treatments to the chin and cheeks, spaced 2 weeks apart.
Number of subjects: 87
Study 36533798 — intervention group
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA-lanm for injection (DAXI) 40U (glabellar), 32U (forehead), 48U (lateral canthal)
Number of subjects: 48
Study 36533856 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating ASCs in primary SS patients
Number of subjects: 21
Study 36533856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mature phenotype of ASCs in primary SS patients
Number of subjects: 21
Study 36533856 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory CXCR3+ phenotype of ASCs
Number of subjects: 21
Study 36533856 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maturity index of ASCs
Number of subjects: 21
Study 36533856 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency and/or maturity of ASCs
Number of subjects: 21
Study 36533915 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ECG abnormalities (major and minor)
Number of subjects: 155
Study 36533915 — intervention group
Group type: EXPERIMENTAL
Intervention: Major early ECG abnormalities
Number of subjects: 155
Study 36533915 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, preexisting ultimately fatal comorbidity, and cerebral insult as the cause of SE
Number of subjects: 155
Study 36533948 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted, inactivated vaccines
Number of subjects: 0
Study 36533948 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza virus vaccine
Number of subjects: 0
Study 36533948 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza virus vaccines without adjuvant
Number of subjects: 0
Study 36534160 — intervention group
Group type: EXPERIMENTAL
Intervention: Lete-cel alone (arm 1)
Number of subjects: 6
Study 36534160 — intervention group
Group type: EXPERIMENTAL
Intervention: Lete-cel with pembrolizumab (arm 2)
Number of subjects: 6
Study 36534165 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 41
Study 36534165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 36534208 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib plus MTX
Number of subjects: 530
Study 36534208 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib monotherapy
Number of subjects: 530
Study 36534217 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of macrophages
Number of subjects: 1003
Study 36534217 — intervention group
Group type: EXPERIMENTAL
Intervention: Small minimum lumen area
Number of subjects: 1003
Study 36534217 — intervention group
Group type: EXPERIMENTAL
Intervention: Large lipid arc (> 180°)
Number of subjects: 1003
Study 36534217 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin fibrous cap and large macrophage infiltration (> 67°)
Number of subjects: 1003
Study 36534268 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36534274 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 20 mg subcutaneously
Number of subjects: 284
Study 36534365 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic education and physical activity (TEPA)
Number of subjects: 46
Study 36534365 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - received two educational group sessions on fatigue and physical activity
Number of subjects: 46
Study 36534451 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide treatment
Number of subjects: 0
Study 36534451 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 36534461 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated screening using natural language processing (NLP) for 12 months
Number of subjects: 0
Study 36534461 — intervention group
Group type: COMPARATOR
Intervention: Manual screening by nurses and social workers for 12 months
Number of subjects: 0
Study 36534461 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated screening
Number of subjects: 0
Study 36534461 — intervention group
Group type: COMPARATOR
Intervention: Manual screening
Number of subjects: 0
Study 36534474 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate initiation of antibiotics after culture
Number of subjects: 186
Study 36534474 — intervention group
Group type: COMPARATOR
Intervention: Specimen-initiated antibiotic protocol
Number of subjects: 186
Study 36534492 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR)
Number of subjects: 47
Study 36534492 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT)
Number of subjects: 47
Study 36534492 — intervention group
Group type: COMPARATOR
Intervention: Control (Passive Recovery)
Number of subjects: 47
Study 36534493 — intervention group
Group type: EXPERIMENTAL
Intervention: cAngio-IMR (contrast-flow angio-IMR)
Number of subjects: 104
Study 36534493 — intervention group
Group type: COMPARATOR
Intervention: thermo-IMR (thermodilution-derived IMR)
Number of subjects: 104
Study 36534493 — intervention group
Group type: EXPERIMENTAL
Intervention: cAngio-IMR
Number of subjects: 104
Study 36534647 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole (Bz)
Number of subjects: 234
Study 36534647 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifurtimox (Nf)
Number of subjects: 234
Study 36534665 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized auditory training program
Number of subjects: 0
Study 36534665 — intervention group
Group type: COMPARATOR
Intervention: Nonpersonalized Active Control program
Number of subjects: 0
Study 36534705 — intervention group
Group type: EXPERIMENTAL
Intervention: Population heterogeneity analysis
Number of subjects: 0
Study 36534705 — intervention group
Group type: EXPERIMENTAL
Intervention: Model fitting and data analysis
Number of subjects: 0